On May 20, the Council for Innovation Promotion (C4IP) sent a letter addressed to the U.S. Senate Committee on the Judiciary one day before the committee held a hearing on competition and consumer pricing in the prescription drug market. C4IP’s letter pushes back against common myths about the impact of patents on drug prices, some of which were the focus of debate during the Judiciary Committee hearing this week, to better inform Congressional efforts on expanding access to medicines for American consumers.
Recent Posts
- Other Barks and Bites for Friday, June 15: U.S. Chamber Calls Out Senator Sanders for Abuse of Power, USPTO Creates Process to De-Designate Precedential PTAB Decisions, and Roche Sues Indian Sellers of Expired Accu-Chek Devices
- SCOTUS Reverses CAFC’s ‘TRUMP TOO SMALL’ Ruling: Names Clause is Constitutional
- AI and the Word that’s Been Missing from the Patent Eligibility Case Law
- USPTO Finalizes Changes to PTAB Pre-Issuance Circulation Rules
- IPWatchdog Unleashed: The Unified Patent Court One Year In, with Tobias Wuttke